Developing novel strategies for immunoprevention of estrogen receptor-negative breast cancer

Ended Project Grant Awarded Last action

Award ID
W81XWH2210060
Recipient
Awarding agency
Obligated
$729,000

Award facts

Assistance listing
12.420 Military Medical Research and Development
Completion date
Place of performance
Houston, TX 77030, USA

Award details come from USAspending.gov.

About this award

The University of Texas MD Anderson Cancer Center received a $729,000 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420) to support research developing novel strategies for immunoprevention of estrogen receptor-negative breast cancer. The three-year award, issued on December 31, 2021 with a completion date of December 30, 2024, will fund applied and advanced biomedical research investigating medical solutions for breast cancer prevention through innovative immunotherapeutic approaches. As the prime awardee, MD Anderson Cancer Center will leverage its expertise in cancer immunology and immunotherapy to develop strategies that could transform breast cancer prevention for both military service members and the general public.

Quick answers

Who received award W81XWH2210060?

W81XWH2210060 was awarded to The Univeristy Of Texas M.d. Anderson Cancer Center by Medical Command (Department of the Army) on December 31, 2021.

How much is award W81XWH2210060 worth?

$729,000 has been obligated on W81XWH2210060.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award